Wikipedia:Articles for deletion/Afasevikumab


 * The following discussion is an archived debate of the proposed deletion of the article below. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review).  No further edits should be made to this page.

The result was moved to user space. (non-admin closure) --  Dane talk  18:56, 12 January 2018 (UTC)

Afasevikumab

 * – ( View AfD View log  Stats )

No evidence of notability. According to what I could find online, development was abandoned at phase I. Rule of thumb for experimental drug notability requires phase II trials. Natureium (talk) 19:56, 8 January 2018 (UTC)


 * Userfy per nom. --Tyranitar Man (talk) 20:33, 8 January 2018 (UTC)
 * Note: This discussion has been included in the list of Medicine-related deletion discussions. Baby miss  fortune 02:54, 9 January 2018 (UTC)


 * Considering that (who commented above in favor of userfying) is the sole contributor of the article, I am going to go ahead, move a copy to their userspace, and tag the mainspace for speedy.  Tigraan Click here to contact me 16:54, 9 January 2018 (UTC)
 * Moved to User:Tyranitar Man/Afasevikumab, and speedy requested for the redirect currently in place. If anyone contests, feel free to revert my actions. It is probably best to keep the AfD open for a day or so, though. Tigraan Click here to contact me 16:59, 9 January 2018 (UTC)


 * The above discussion is preserved as an archive of the debate. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review). No further edits should be made to this page.